MAPT and Cognitive impairment: Notably, recent research has shown promising results, demonstrating that specific NLRP3 inhibitors attenuated the NLRP3 inflammasome activity in vivo, reduced tau and Aβ levels, and diminished cognitive impairment [9–11].